Overexpression of connexin 43 using a retroviral vector improves electrical coupling of skeletal myoblasts with cardiac myocytes in vitro by Tolmachov, Oleg et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Overexpression of connexin 43 using a retroviral vector improves 
electrical coupling of skeletal myoblasts with cardiac myocytes in 
vitro
Oleg Tolmachov*†1, Yu-Ling Ma†2, Michael Themis1, Pravina Patel2, 
Hilmar Spohr2, Kenneth T MacLeod3, Nina D Ullrich3, Yvonne Kienast1, 
Charles Coutelle1 and Nicholas S Peters2
Address: 1Section of Molecular and Cellular Medicine, Division of Biomedical Sciences, Faculty of Life Sciences, Imperial College London, London, 
UK, 2Department of Cardiac Electrophysiology, National Heart and Lung Institute, Imperial College London at St. Mary's Hospital, London, UK 
and 3Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
Email: Oleg Tolmachov* - o.tolmachov@imperial.ac.uk; Yu-Ling Ma - y.ma@imperial.ac.uk; Michael Themis - m.themis@imperial.ac.uk; 
Pravina Patel - pravina.patel@imperial.ac.uk; Hilmar Spohr - h.spohr@imperial.ac.uk; Kenneth T MacLeod - k.t.macleod@imperial.ac.uk; 
Nina D Ullrich - n.ullrich@imperial.ac.uk; Yvonne Kienast - y.kienast@gmx.de; Charles Coutelle - c.coutelle@imperial.ac.uk; 
Nicholas S Peters - n.peters@imperial.ac.uk
* Corresponding author    †Equal contributors
Abstract
Background: Organ transplantation is presently often the only available option to repair a damaged heart. As heart
donors are scarce, engineering of cardiac grafts from autologous skeletal myoblasts is a promising novel therapeutic
strategy. The functionality of skeletal muscle cells in the heart milieu is, however, limited because of their inability to
integrate electrically and mechanically into the myocardium. Therefore, in pursuit of improved cardiac integration of
skeletal muscle grafts we sought to modify primary skeletal myoblasts by overexpression of the main gap-junctional
protein connexin 43 and to study electrical coupling of connexin 43 overexpressing myoblasts to cardiac myocytes in
vitro.
Methods: To create an efficient means for overexpression of connexin 43 in skeletal myoblasts we constructed a
bicistronic retroviral vector MLV-CX43-EGFP expressing the human connexin 43 cDNA and the marker EGFP gene. This
vector was employed to transduce primary rat skeletal myoblasts in optimised conditions involving a concomitant use of
the retrovirus immobilising protein RetroNectin® and the polycation transduction enhancer Transfectam®. The EGFP-
positive transduced cells were then enriched by flow cytometry.
Results: More than four-fold overexpression of connexin 43 in the transduced skeletal myoblasts, compared with non-
transduced cells, was shown by Western blotting. Functionality of the overexpressed connexin 43 was demonstrated by
microinjection of a fluorescent dye showing enhanced gap-junctional intercellular transfer in connexin 43 transduced
myoblasts compared with transfer in non-transduced myoblasts. Rat cardiac myocytes were cultured in multielectrode
array culture dishes together with connexin 43/EGFP transduced skeletal myoblasts, control non-transduced skeletal
myoblasts or alone. Extracellular field action potential activation rates in the co-cultures of connexin 43 transduced
skeletal myoblasts with cardiac myocytes were significantly higher than in the co-cultures of non-transduced skeletal
myoblasts with cardiac myocytes and similar to the rates in pure cultures of cardiac myocytes.
Conclusion: The observed elevated field action potential activation rate in the co-cultures of cardiac myocytes with
connexin 43 transduced skeletal myoblasts indicates enhanced cell-to-cell electrical coupling due to overexpression of
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connexin 43 in skeletal myoblasts. This study suggests that retroviral connexin 43 transduction can be employed to
augment engineering of the electrocompetent cardiac grafts from patients' own skeletal myoblasts.
Background
There is only minor potential for cell renewal in the adult
myocardium [1]. Loss of myocardial cells due to cardiac
disease results in impairment of cardiac contractile and
electrical function, and despite currently available medi-
cal therapies the mortality rate remains substantial and
worsens with deteriorating myocardial function [2]. Car-
diac transplantation is currently the treatment offered to
selected patients with end-stage left ventricular dysfunc-
tion, but due to limited donor supply and resources, this
mode of therapy will remain confined to a minority of
patients [3].
Cell transplantation is a promising means of repairing
damaged myocardium. A number of different cell types
and their combinations are under investigation for trans-
plantation to the ventricular myocardium, including neo-
natal or fetal cardiomyocytes, autologous skeletal
myoblasts, fibroblasts, hematopoetic stem cells, and
embryonic stem cell-derived cells [4-6]. Transplanted cells
have been widely reported to engraft into the host myo-
cardium, but with variability in the degree of differentia-
tion and integration with the host tissue [7-9].
Owing to immunological, ethical and practical advan-
tages over some of the other cell types, transplantation of
autologous skeletal myoblasts for myocardial repair was
the first to undergo clinical trials [10,11]. Although mod-
est improvements of cardiac function have been reported,
ventricular tachycardia was observed in a number of
patients indicating absence of electrical incorporation of
the grafted cells into the host myocardium. In general, the
results obtained from cell, animal and human studies
have indicated that the implanted myoblasts showed
fusion and differentiated into multinucleated myotubes,
did not transdifferentiate to cardiac myocytes and did not
couple with the host cardiac myocytes. It is possible that
lack of electrical coupling of the implanted cells with the
host myocytes is the key factor blocking adequate func-
tional incorporation of the grafted skeletal myoblasts into
the beating cardiac muscle [12]. Indeed, the major myo-
cardial gap junctional protein connexin 43 is not
expressed in mature skeletal myotubes [13]. We therefore
addressed the hypothesis that connexin 43 overexpression
by retroviral transduction of the skeletal myoblasts can
enhance their electrical integration with cardiac myocytes
in co-culture.
Methods
E. coli strain, transformation and bacterial culture 
conditions
E. coli strain DH10B F-  mcrA  ∆(mrr-hsdRMS-mcrBC)
ϕ80lacZ∆M15  ∆lacX74 recA1 endA1 araD139 ∆(ara,
leu)7697 galU galK λ- rpsL(StrR) nupG (Invitrogen) was
used as a plasmid host. This strain was transformed by
electroporation using the Gene Pulser® II apparatus (Bio-
Rad). Bacterial clones were cultured in the LB medium
supplemented with appropriate antibiotics [14].
Plasmids, oligonucleotides, PCR and sequencing
Plasmid pGF1 containing human connexin 43 cDNA [15]
and primers CX-NHE 5'-TACTGCAGAA GCTAGCAGCC
GCCACCATGG GTGACTGGAG CGCCTTAGGC-3' and
CX-BAM 5'-TGTTACTATA GGATCCCTAG ATCTCCAGGT
CATCAGGCC-3' were employed to amplify the connexin
43 gene by PCR using high fidelity Pfx DNA polymerase
(Invitrogen). The forward PCR primer CX-NHE included
a recognition sequence for NheI followed by the consen-
sus extended Kozak sequence 5'-GCCGCCACC-3'. The
reverse PCR primer CX-BAM contained a BamHI recogni-
tion sequence at its 5' end. The obtained PCR product was
cut by NheI and BamHI and inserted into the NheI and
BamHI digested plasmid pIRES2EGFP (Clontech) to pro-
duce the new plasmid pCX43-IRES-EGFP. Then the entire
connexin 43 cDNA insert was sequenced (Advanced Bio-
technology Centre, Imperial College London) using prim-
ers CX-SEQ2 5'-TTGCTGCGAACCTACATCATCAGT-3',
CX-SEQ3 5'-TTTCAATGGC TGCTCCTCACCAAC-3' and
CX-SEQ4 5'-GAAGATGGTTTTCTCCGTGGGGCGAGA-3'
to confirm its faithful reproduction by PCR.
The CX43-IRES-EGFP bicistronic expression cassette was
excised using AseI and NotI to include the CMV promoter
but to exclude the SV40 polyadenylation signal. This frag-
ment was blunt-ended by the Klenow fragment of
Escherichia coli DNA polymerase I (KF) and inserted
between KF-polished EcoRI and NotI ends of the digested
retroviral MLV vector plasmid pLZRS-LacZ(A) [16]. The
resultant retroviral vector plasmid was called pMLV-
CX43-EGFP (Figure 1).
Tissue culture techniques and construction of the producer 
cell line generating retroviral vector MLV-CX43-EGFP
Packaging cells, virus producer cells, and immortalised L6
rat myoblasts (ATCC CRL-1458) were grown in DMEM
with glutamax-I supplemented with 10% FCS (Invitro-
gen) at 37°C with 5% CO2 in air.BMC Cardiovascular Disorders 2006, 6:25 http://www.biomedcentral.com/1471-2261/6/25
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To generate retroviral producer cell lines, the amphotropic
MLV packaging cell line TEFLYA [17] was transfected with
the obtained plasmid pMLV-CX43-EGFP. Transfection
was performed using Lipofectamin® (Invitrogen) as rec-
ommended by the supplier. Transfected cells were
selected in the medium supplemented with puromycin
(10 µg/ml). Different dilutions of the trypsinised trans-
fected cells were prepared and seeded onto 96 well plates.
267 individual clones were produced and expanded in 24
well plates. The clones were screened using an inverted
fluorescence microscope (Leitz) for EGFP expression and
also for viral vector production by transduction of L6 rat
skeletal myoblasts. 39 clones (14.6%) were fluorescent of
which 17 clones (6.4%) produced virus. Screening of
supernatants from 267 potential producer cell lines
revealed a broad variation in the titre of produced virus,
determined by transduction of L6 rat skeletal myoblasts in
the presence of 10 µg/ml of Polybrene™. Clones A113,
A189 and A247 produced virus with the highest end-point
titre (1 × 106 TU/ml in the freshly collected virus-contain-
ing medium). Clone A247 was used as a source of the
MLV-CX43-EGFP virus vector for further experiments.
Virus vector preparations were produced by centrifugation
of culture supernatants from producer cells at 5000 rpm
for 10 min and filtration of the obtained fluid through 0.8
µm filters (Sartorius). The virus vector preparations were
stored frozen at -80°C.
Isolation and culture of skeletal myoblasts and cardiac 
myocytes
The manipulations of animals in this work conform to UK
Home Office guidelines. Primary rat skeletal myoblasts
were isolated from the hind leg muscles of adult male
Wistar rats. The muscle slices were digested in 0.25% pan-
creatin, 1% trypsin for 1 hour with occasional agitation.
The isolated cells were collected by filtering through 70
µm nylon cell strainers (Falcon). Counter-selection
against fibroblasts was accomplished by 2 rounds of dif-
ferential adhesion on collagen coated tissue culture flasks
(40 min at 37°C for each adhesion step). Primary myob-
lasts were cultured in a CO2 incubator at 37°C in DMEM
with glutamax-I (Invitrogen) supplemented with 20%
FCS and further purified by sorting using paramagnetic
beads (Dynal Biotech) coated with antibody H36 against
myoblast specific α-7 integrin [18].
Cardiac myocytes were isolated from neonatal rats.
Freshly excised ventricles were dissociated in trypsin-
EDTA (Invitrogen) and the dispersed cells were suspended
in the culture medium, a 4:1 mixture of DMEM and M199
media (Invitrogen) supplemented with 15% horse serum
and 5% FCS. The cell suspension was pre-plated to sepa-
rate fibroblasts from myocytes as described for skeletal
myoblasts above. The myocytes remaining in the suspen-
sion were cultured in a CO2 incubator at 37°C.
Retroviral transduction of primary skeletal myoblasts and 
FACS analysis
Filtered preparation of the MLV-CX43-EGFP was poured
into RetroNectin® (TaKaRa) coated plates for the virions to
attach. Myoblasts were loaded onto the immobilised viral
vector particles in the DMEM supplemented with 20%
FCS and, optionally, 5 µg/ml Transfectam® (dioctadecyla-
midoglycyl spermine, DOGS, Promega) or 10 µg/ml Poly-
brene™ (hexadimethrine bromide, Sigma). The
proportion of the transduced cells was determined by
FACS analysis on a FACSCalibur machine (Becton Dickin-
son) relying on expression of the EGFP transgene. The
total number of counted cells was 10000 in all FACS
measurements. The transduced cells were sorted using a
preparative FACS machine (Becton Dickinson FACS DIVA
cell sorter) to produce a cell population with more than
70% of the cells expressing the EGFP marker (Figure 2D).
The sorted cells were passaged once and their myogenic
nature was confirmed by immunoconfocal analysis with a
monoclonal anti-desmin antibody (clone DE-U-10, prod-
Plasmid pMLV-CX43-EGFP containing the DNA sequence  for the retroviral vector MLV-CX43-EGFP Figure 1
Plasmid pMLV-CX43-EGFP containing the DNA 
sequence for the retroviral vector MLV-CX43-EGFP. 
A retroviral backbone plasmid, pMLV-CX43-EGFP, co-
expressing human connexin 43 cDNA and the EGFP gene, 
was generated on the basis of the retroviral backbone plas-
mid pLZRS-LacZ(A). We used the internal ribosome entry 
site (IRES) to arrange the connexin 43 sequence and the 
downstream EGFP marker gene within one single transcrip-
tion unit under control of a tandem of MLV LTR promoter 
and CMV immediate early promoter. The obtained plasmid 
pMLV-CX43-EGFP contains the Epstein-Barr virus EBNA-1-
oriP segment driving episomal replication in the producer 
cell line and, thus, improving chances for selection of a high 
titre virus producing clone. The EGFP marker of the retrovi-
ral vector simplifies identification of transduced cells and is 
useful for evaluation of the viral vector titre.
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Transduction of primary rat skeletal myoblasts by the retroviral vector MLV-CX43-EGFP and resultant overexpression of con- nexin 43 Figure 2
Transduction of primary rat skeletal myoblasts by the retroviral vector MLV-CX43-EGFP and resultant over-
expression of connexin 43. Connexin 43 and EGFP were expressed from a single bicistronic transcription unit. (A) Trans-
duction of primary rat skeletal myoblasts using various dilutions of the MLV-CX43-EGFP viral vector preparation. Medium in 
the wells of a 24-well plate containing non-confluent primary myoblasts was aspirated and the wells were filled with 1 ml of the 
non-diluted and diluted viral vector suspensions supplemented with Polybrene™ (10 µg/ml). After 48 hours the cells were 
trypsinised, washed in complete DMEM medium, resuspended in PBS and used for FACS analysis to determine the efficiency of 
transfection relying on EGFP expression. The obtained data were averaged among 3 wells for each virus vector dilution. (B) 
Concomitant use of RetroNectin®-mediated viral vector concentration and polycation transduction enhancement for delivery 
of the connexin 43 and EGFP genes into primary skeletal myoblasts using MLV-CX43-EGFP vector. Transduction experiments 
were performed in 6-well plates containing non-confluent myoblasts in the presence of the polycation Polybrene™ (10 µg/ml), 
in the presence of the polycation Transfectam® (5 µg/ml) or without addition of polycations. The efficiency of transduction was 
determined using the EGFP marker from the FACS subtraction plots using non-transduced primary skeletal myoblasts as a con-
trol, non-fluorescent cell population. The data were averaged among 6 individual transduction experiments. (C) Fractions of 
EGFP-positive cells in the population of connexin 43/EGFP transduced primary skeletal myoblasts during continuous passaging. 
The cells were split and re-seeded in the ratio 1:10 each week with concomitant FACS measurement of the fraction of the 
EGFP-expressing cells. (D) Results of FACS analysis of populations of primary skeletal myoblasts plotted as histograms (x-axis 
– intensity of green fluorescence, y-axis – counts of cells). Purple graph corresponds to non-transduced primary skeletal myob-
lasts, red graph corresponds to the primary skeletal myoblasts after RetroNectin®-mediated Transfectam®-enhanced transduc-
tion by MLV-CX43-EGFP, green graph represents primary skeletal myoblasts, which were preparatively sorted for EGFP 
expression after transduction by MLV-CX43-EGFP. (E) Western blotting analysis of connexin 43 expression in connexin 43 
transduced skeletal myoblasts (after EGFP-based preparative sorting). The cell extracts were analysed by electrophoresis in a 
SDS-PAGE gel and immunoblotting using anti-connexin 43 antibody. Lane 1 corresponds to non-transduced primary skeletal 
myoblasts, lane 2 corresponds to connexin 43 transduced primary skeletal myoblasts, lane 3 corresponds to connexin 43 
transduced primary skeletal myoblasts, which were passaged 13 weeks in tissue culture.
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uct number D033 from Sigma-Aldrich) as shown in Addi-
tional file 2: Additional_file_2.pdf.
The obtained population of connexin 43 transduced
myoblasts was frozen in liquid nitrogen in the DMEM
containing 20% FCS and 10% DMSO. Aliquots of the fro-
zen transduced skeletal myoblasts were used to seed sub-
cultures for Western blotting analysis, dye transfer and
electrophysiological experiments.
Western blotting analysis of connexin 43 expression
Quantitative immunoblotting was performed to confirm
overexpression of connexin 43 in the skeletal myoblasts
containing the connexin 43 transgene. Seeded cells were
allowed to expand until they reached complete conflu-
ence (7 days). Then the cells were scraped off, homoge-
nised in the lysis buffer SB20 (20% SDS and 0.15 M Tris-
HCl pH 6.8) and sonicated to shear the genomic DNA.
The protein concentration was determined and adjusted
to 0.5 mg/ml. Samples with 5.0 µg of total protein were
resolved by SDS-PAGE on a 12.5% gel and transferred
onto a polyvinylidene difluoride membrane. The mouse
primary antibody against connexin 43 (Chemicon), the
secondary alkaline phosphatase-conjugated anti-mouse
antibody (Pierce) and the proprietary alkaline phos-
phatase substrate (Promega) were used to detect connexin
43. The protein bands were quantified by densitometry.
Two independent cell cultivation experiments were per-
formed and two independent gels were analysed by West-
ern blotting for each cultivation experiment.
Microinjection and intercellular transfer of a fluorescent 
dye
Skeletal myoblasts transduced with the MLV-CX43-EGFP
vector, control non-transduced skeletal myoblasts and co-
cultures of these cells with cardiac myocytes were grown
in culture dishes to ~80% confluence. The culture dishes
were then placed onto the stage of an inverted fluores-
cence microscope. Microelectrodes with resistance 50–60
MΩ were loaded with a 5% solution of Cascade Blue
derivative 8-methoxypyrene-trisulphonic acid (Molecular
Probes, Oregon, USA) and were back-filled with 1 M LiCl.
The dye was iontophoresed into each cell by 4–6 nA cur-
rent for 2 min following impalement of a cell by the elec-
trode. Dye transfer to the adjacent cells was recorded using
a Nikon digital camera (Coolpix 990). Dye transfer
images were captured 2 min after injection. The images
were used to score the number of neighbouring cells to
which the dye was transferred from each injected cell.
Electrophysiological measurements in cell co-cultures
Cell culture dishes incorporating a group of 60 embedded
unipolar electrodes with diameter 30 µm with interelec-
trode distances of 100 µm (Multielectrode Array, MCS
GmbH, Reutlingen, Germany) were used to study and
compare the electrical integration of skeletal myoblasts
(connexin 43/EGFP transduced and non-transduced) in
co-cultures with cardiac myocytes. Five groups of cell cul-
tures were under investigation: 1) cardiac myocytes alone;
2) skeletal myoblasts alone; 3) connexin 43 transduced
skeletal myoblasts alone; 4) cardiac myocytes co-cultured
in a ratio of 4:1 with connexin 43 transduced skeletal
myoblasts; 5) cardiac myocytes co-cultured in the same
ratio with non-transduced skeletal myoblasts. To establish
co-cultures, cardiac myocytes were seeded in the multie-
lectrode array dishes (1 million cells per dish) to allow the
cells to settle. The cells were cultured in a medium com-
posed of a 4:1 mixture of DMEM and M199 media (Invit-
rogen) supplemented with 15% horse serum and 5% FCS.
At day 2 after the initial seeding, connexin 43 transduced
skeletal myoblasts or non-transduced skeletal myoblasts
(0.25 million cells per dish) were added to cardiac myo-
cytes. At day 3, the cells reached confluence with both
skeletal and cardiac cells distinguishable under the micro-
scope. Then MEA dishes were placed onto the recording
system and an extracellular stimulatory current was
applied in 10 evenly spaced pulses (80 µA, 5 ms) during
10 s time interval. The stimulatory pulses were delivered
to the cells by a pair of electrodes located outside the 60-
electrode array. To register FAP, electrograms (potential
against time) were recorded for 10 s. The FAP activation
rate (that is, frequency of FAP firing) was determined from
the discrete spikes on the electrograms with amplitude >
500 µV and duration > 5 ms using the spike sorter of the
MC-Rack data analyser (Microcal Software, Northampton,
MA, USA). The FAP activation rate data obtained from the
60 electrodes were then averaged.
Statistical analysis
The data are presented as the mean value and its standard
error (mean ± standard error, M ± SE). The following for-
mula was used to compute average standard error (ASE) of
the ratio of two means (M1 ± SE1, M2 ± SE2): ASE = (M1/
M2)*(SE1
2/M1
2+SE2
2/M2
2)1/2. The significance of the dif-
ferences between experimental groups was estimated
using unpaired t-test.
Results
Construction of the retroviral connexin 43 vector MLV-
CX43-EGFP and optimisation of myoblast transduction 
conditions
To be able to deliver the connexin 43 gene to skeletal
myoblasts we constructed an amphotropic retroviral vec-
tor MLV-CX43-EGFP, co-expressing human connexin 43
cDNA and the EGFP marker gene (Figure 1).
The passaging time of primary skeletal myoblasts in tissue
culture before transplantation is limited because of clini-
cal considerations. Therefore, it is important to achieve
maximum cell transduction efficiency with a minimalBMC Cardiovascular Disorders 2006, 6:25 http://www.biomedcentral.com/1471-2261/6/25
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number of exposures of the myoblasts to the viral vector.
Amphotropic MLV vector preparations commonly con-
tain substances, which severely limit the efficiency of
transduction. In an attempt to minimise the adverse effect
of the transduction inhibitors, we used various dilutions
of the MLV-CX43-EGFP viral vector preparation with end-
point titre 2 × 105 TU/ml for infection of the primary rat
skeletal myoblasts in the presence of 5 µg/ml of the com-
monly used transduction enhancer polycation Poly-
brene™ (hexadimethrine bromide). The highest efficiency
of transduction (9.94 ± 0.50%) was achieved with 5-fold
dilution of the viral vector and not with undiluted vector,
confirming contamination of the vector preparation by
transduction inhibitors (Figure 2A). To increase efficiency
of transduction by the MLV-CX43-EGFP vector, we tested
RetroNectin®-mediated virion capture [19] to immobilise
the vector particles on a plastic surface and, thus, to get rid
of the RetroNectin®-unbound portion of the transduction
inhibitors. We compared the standard RetroNectin®-medi-
ated transduction protocol, which is performed without
polycation transduction enhancers, to RetroNectin®-
mediated transduction in the presence of Polybrene™ or,
alternatively, in the presence of lipopolyamine Trans-
fectam®  (dioctadecylamidoglycyl spermine, [20]). The
obtained transduction efficiency data are summarised in
Figure 2B. Employment of Transfectam® to enhance trans-
duction of primary skeletal myoblasts by RetroNectin®-
immobilized MLV-CX43-EGFP vector allowed transduc-
tion of 38.30 ± 0.89% cells. In contrast, the efficiency of
transduction was 22.56 ± 0.75% in the RetroNectin®/Poly-
brene™ experiments and 14.34 ± 0.60% when RetroNec-
tin®-immobilised virus was used without addition of a
polycation substance.
To estimate the stability of connexin 43 expression, one
part of the transduced population of skeletal myoblasts
was stored frozen in liquid nitrogen and another part was
used for continuous passaging. During 12-week cultiva-
tion, the cells were split and re-seeded in the ratio 1:10
each week with simultaneous FACS analysis of the EGFP
transgene expression. The percentage of EGFP-positive
cells stayed practically constant during passaging in vitro
indicating absence of the EGFP transgene shut-down and
suggesting the absence of shut-down of the linked con-
nexin 43 transgene (Figure 2C).
The passaged and the stored populations of transduced
myoblasts were then used for preparative FACS to enrich
EGFP expressing cells to more than 70% (Figure 2D).
Western blotting analysis showed a 4.85 ± 0.25 times
overexpression of connexin 43 in the population of sorted
non-passaged MLV-CX43-EGFP transduced skeletal
myoblasts compared with control non-transduced skele-
tal myoblasts. Confirming longevity of connexin 43
expression in tissue culture, Western blotting analysis
showed a 4.71 ± 0.23 times overexpression of connexin
43 in the population of passaged sorted skeletal myob-
lasts compared with non-transduced skeletal myoblasts
(Figure 2E).
Connexin 43 overexpression enhances intercellular dye 
transfer between skeletal myoblasts
To show that connexin 43 overexpression has improved
intercellular communication in skeletal myoblasts, we
injected fluorescent dye 8-methoxypyrene-trisulphonic
acid (a Cascade Blue derivative) into individual cells in
pure cultures of connexin 43 transduced and non-trans-
duced skeletal myoblasts (Figure 3). 13 injections of the
dye were carried out in the cultures of connexin 43 trans-
duced skeletal myoblasts, 10 of them (77%) resulted in
dye migration to the neighbouring cells. In contrast, just 3
out of 11 (27%) injections led to intercellular dye spread
in non-transduced skeletal myoblasts. The number of cells
to which the dye permeated from the injected cell varied
and was 1.38 ± 0.33 for connexin 43 transduced cells and
0.27 ± 0.14 for non-transduced ones. Thus, enhanced dye
spread to neighbouring cells was observed in connexin 43
transduced skeletal myoblasts compared with non-trans-
duced ones (P < 0.05), indicating a higher density of gap
junctions in the cells overexpressing connexin 43.
Connexin 43 overexpression in skeletal myoblasts 
improves electrical coupling in co-cultures of cardiac 
myocytes and skeletal myoblasts
Co-cultures of skeletal myoblasts and cardiac myocytes
were established to mimic in vivo transplantation of skel-
etal myoblasts to the host myocardium. The cells were
grown in multielectrode array (MEA) assemblies, which
allowed application of stimulatory current pulses and
recording of field action potentials (FAPs) propagating in
the cell population using 60 electrodes (Figure 4AC).
Spontaneous FAPs were observed in 100% (5 out of 5) of
cultures of pure cardiac myocytes, 40% (4 out of 10) of co-
cultures of connexin 43 transduced skeletal myoblasts
with cardiac myocytes and 12.5% (1 out of 8) of co-cul-
tures of non-transduced skeletal myoblasts with cardiac
myocytes. In the latter case FAP activation had a sporadic
pattern. Stimulation with 10 pulses of current applied
during 10 s was sufficient to obtain FAPs in 100% (10 out
of 10) of co-cultures of connexin 43 transduced skeletal
myoblasts with cardiac myocytes and 25% (2 out of 8) of
co-cultures of non-transduced skeletal myoblasts with car-
diac myocytes. Again, in the latter case the pattern of FAP
activation was always only sporadic. No FAP activation
was observed in 10 individual cultures of non-tranduced
skeletal myoblasts and 10 individual cultures of trans-
duced skeletal myoblasts. Typical electrograms are pre-
sented in Figure 4BD (illustration for all 60 electrodes is
shown in Additional file 1: Electrograms.pdf). The meanBMC Cardiovascular Disorders 2006, 6:25 http://www.biomedcentral.com/1471-2261/6/25
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Intercellular fluorescent dye microinjection in connexin 43 and EGFP transduced and non-transduced primary skeletal myob- lasts Figure 3
Intercellular fluorescent dye microinjection in connexin 43 and EGFP transduced and non-transduced primary 
skeletal myoblasts. Cascade Blue derivative 8-methoxypyrene-trisulphonic acid was used as a fluorescent dye. Panel 'ABCD' 
shows fluorescent dye microinjection experiment in a culture of non-transduced primary skeletal myoblasts. Panel 'EFGH' 
shows fluorescent dye microinjection experiment in a culture of connexin 43 and EGFP transduced primary skeletal myoblasts. 
All pictures were taken using 400 times instrumental magnification. Blue fluorescence was visualised using Nikon filter block 
UV-1A (DM400). Green fluorescence was visualised using a standard 'FITC' filter block. (A) A phase contrast image of a group 
of adjacent non-transduced skeletal myoblasts. (B) An image of the injection microelectrode inserted into one of the adjacent 
cells under UV light. (C) An image of the same group of the cells under UV light after 2 min, no dye transfer. (D) An overlay 
of 'A' and 'C'. (E) An image of a group of adjacent connexin 43 and EGFP transduced skeletal myoblasts under UV light before 
dye injection (green fluorescence confirms EGFP expression). (F) An image of the injection microelectrode inserted into one 
of the adjacent cells under UV light. (G) An image of the same group of cells under UV light after 2 min, the dye is transferred 
to adjacent cells. (H) An overlay of 'E' and 'G'.BMC Cardiovascular Disorders 2006, 6:25 http://www.biomedcentral.com/1471-2261/6/25
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FAP activation rate for the 60 electrodes over 10 s after the
last stimulation pulse was 2.74 ± 0.20 Hz for cardiac myo-
cytes alone, 1.97 ± 0.34 Hz for co-culture of connexin 43
transduced skeletal myoblasts with cardiac myocytes (no
significant difference compared with cardiac myocytes
alone) and 0.44 ± 0.19 Hz for co-culture of non-trans-
duced skeletal myoblasts with cardiac myocytes (P <
0.001 compared with cardiac myocytes alone, and P <
0.002 compared with co-culture of connexin 43 trans-
duced skeletal myoblasts with cardiac myocytes).
Thus, a comparison of all the experimental groups indi-
cated that electrical coupling in the co-culture of skeletal
myoblasts with cardiac myocytes is significantly enhanced
in the presence of overexpressed connexin 43.
Discussion
Electric communication between cells is mediated by
bursts of the action potential and gap junctions provide
the low resistance pathway for its cell-to-cell propagation.
In addition gap junctions mediate flux of small molecules
that regulate normal tissue development and tissue pat-
terning. It is, therefore, reasonable to hypothesise that gap
junctions can play a central role in the electromechanical
incorporation of cardiac grafts. Autologous skeletal myob-
lasts are an attractive source for cardiac transplants
because of their immune privileges, availability and non-
tumourogenicity (reviewed in [21]). However, when skel-
etal myoblasts differentiate into myotubes, they perma-
nently lose expression of the major gap junctional
protein, connexin 43, and, thus, do not have the appara-
tus for gap-junctional coupling. This is most likely to be
the reason why, after transplantation of skeletal myob-
lasts, the newly developed graft has not been observed
beating synchronously with the heart tissue [22]. There
was no intercellular transfer and electrical coupling
between the cells developed from the transplanted myob-
lasts and the host cardiac myocytes [23]. It was also
reported that human patients with engrafted skeletal
myoblasts suffered from ventricular tachycardia [24,25].
Multi-electrode array recording in co-cultures of primary skeletal myoblasts with cardiac myocytes Figure 4
Multi-electrode array recording in co-cultures of primary skeletal myoblasts with cardiac myocytes. Microscopic 
images of the multi-electrode array (MEA) dishes containing co-cultures of cardiac myocytes with non-transduced (A) or con-
nexin 43/EGFP transduced (C) primary skeletal myoblasts. The images were taken under UV light with 100 times magnifica-
tion. Skeletal myoblasts transduced with MLV-CX43-EGFP vector expressed the EGFP marker and, therefore, were 
fluorescent. Individual recordings (x-axis – time in s, y-axis – potential in µV) from the electrode No. 33 of the MEA in co-cul-
ture of cardiac myocytes with non-transduced skeletal myoblasts (B) and in co-culture of cardiac myocytes with connexin 43/
EGFP transduced skeletal myoblasts (D). These electrograms show the last stimulatory pulse in the series of 10 and the first 
resultant FAP (D) or absence of it (B). Ten stimulatory current pulses were applied with the frequency of 1 Hz.
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Therefore, in pursuit of improved cardiac integration of
skeletal muscle grafts we modified primary skeletal myob-
lasts by overexpression of the main gap-junctional protein
connexin 43.
We have chosen a retroviral MLV vector for delivery and
overexpression of the connexin 43 transgene into skeletal
myoblasts because retroviral vectors are able to integrate
stably into the genome of the transduced cells and thus to
provide long-term expression of a transgene [26]. Indeed,
in our study, expression of connexin 43 and the EGFP
marker in the transduced cells did not subside after 12
weeks of continuous passaging in tissue culture. However,
long term gene expression in vitro can be only tentatively
projected to long term gene expression in vivo, where
transgene expression shutdown events are common [27].
Therefore, one should consider the possible need of 'top-
ping up' connexin 43 gene expression in the transplanted
tissue in vivo. As the engrafted cells do not actively divide,
the choice of the 'topping up' vector is limited to cell divi-
sion independent vectors, for example lentiviral HIV-
based vectors. In this context employment of an MLV vec-
tor at the ex vivo transduction step is beneficial because it
allows subsequent use of efficient and MLV-compatible
lentiviral vectors for additional transduction of the grafts
in vivo. If lentiviral vectors were used for initial transduc-
tion ex vivo, there would be a possibility of a reduced effi-
ciency of the 'topping up' transgene delivery in vivo
because of a CD4-independent superinfection interfer-
ence of the resident lentiviral vector with the incoming
one ([28], reviewed in [29]).
Absence of connexin 43 in adult muscle can be due to
shutdown of the native connexin 43 promoter during
myoblast differentiation. We chose the MLV LTR and the
CMV promoters to drive expression of human connexin
43 cDNA because these viral promoters are known to be
able to direct transcription in adult muscle and therefore
they are unlikely to shut down due to changes in the bal-
ance of transcription factors in the course of myoblast dif-
ferentiation. A tandem arrangement of the two promoters
in the MLV-CX43-EGFP vector could reduce the chances
of transcription silencing after transplantation.
The EGFP marker of the generated viral vector MLV-CX43-
EGFP was useful for the purification of the transduced
cells by FACS and it can also be useful at the post-grafting
stage to track the transplants in vivo.
Our observations show that confluent cultures of primary
myoblasts can stay alive for at least a month in medium
supplemented with FCS (and considerably longer in
medium without serum). This property of primary myob-
lasts was in stark contrast to the transformed rat L6 myob-
lasts, which often died in a week after achieving
confluency. Thus, fortuitously, the number of culture pas-
sages (and, therefore, cell divisions) required for our
manipulation of primarily myoblasts (magnetic sorting,
retroviral transduction, preparative FACS) was lower, than
the number of passages needed for analogous manipula-
tions with a permanent myoblast cell line L6.
To increase the yield of connexin 43 transduced skeletal
myoblasts from a single muscle biopsy it is important to
achieve a high efficiency of transduction by the MLV vec-
tor. However, preparations of amphotropic MLV com-
monly contain infection inhibiting substances, which
reduce maximal transduction efficiencies without reduc-
tion of end-point virus titres [17]. It is, therefore, impor-
tant to optimise conditions for high efficiency of
transduction. In our experiments we have shown for the
first time that a combination of viral vector concentration
on the plastic surface using the virus-binding protein Ret-
roNectin® [19] and transduction in the presence of lipid
polycation Transfectam® [20] is particularly effective for
transduction of primary myoblasts by an amphotropic
MLV vector. The achieved efficiency of transduction
(38.30 ± 0.89%) can be further increased by: 1) improv-
ing the viral vector titre, for example by virion production
at 32°C [30]; 2) additional concentration of the viral vec-
tor, e.g. by using magnetic nanoparticles [31] or low speed
centrifugation [19]; 3) increasing transduction compe-
tence of the recipient cells, for example by phosphate star-
vation of the myoblasts [17] or boosting the myoblast
division rate using growth factors [32].
We have demonstrated that connexin 43 transduction of
skeletal myoblasts and ensuing connexin 43 overexpres-
sion significantly improves propagation of action poten-
tial (measured as FAP activation rate) in co-culture of
cardiac myocytes and skeletal myoblasts in vitro.
Enhanced gap junction formation between connexin 43
transduced skeletal myoblasts and cardiac myocytes is the
most likely mechanism involved. This conjecture is sup-
ported by the results of Reinecke et al [33] who reported
that transplantation of genetically engineered myoblasts,
which were designed to express connexin 43 during differ-
entiation, resulted in close apposition of the skeletal myo-
tubes and the host cardiac myocytes.
Skeletal myoblasts are non-differentiated muscle cells
and, unsurprisingly, we did not observe any FAP activa-
tion in pure cultures of skeletal myoblasts, whether over-
expressing connexin 43 or not. Thus, although fluorescent
dye transfer occurred to a significantly greater extent in
connexin 43 transduced skeletal myoblasts, improved
gap-junctional communication in these cells did not
result in FAP generation. We registered only a limited FAP
activation in co-cultures of non-transduced skeletal
myoblasts with cardiac myocytes. However, with con-BMC Cardiovascular Disorders 2006, 6:25 http://www.biomedcentral.com/1471-2261/6/25
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nexin 43 overexpression in the skeletal myoblasts, the FAP
activation rate in the co-cultures of skeletal myoblasts and
cardiac myocytes was significantly enhanced, and was
close to the FAP activation rate in pure cultures of cardiac
myocytes.
Conclusion
More than 4 times overexpression of connexin 43 in pri-
mary skeletal myoblasts was achieved after retroviral
transduction in optimised conditions involving a con-
comitant use of the retrovirus immobilising protein Retro-
Nectin®  and the polycation transduction enhancer
Transfectam®. Connexin 43 overexpression resulted in
improvement of electrical coupling between transduced
skeletal myoblasts and cardiac myocytes in vitro. Thus, ret-
roviral connexin 43 transduction is a useful step for engi-
neering of electrocompetent cardiac grafts.
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